3/3
07:00 am
enta
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Low
Report
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
2/10
08:05 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/10
07:13 am
enta
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting [Yahoo! Finance]
2/10
07:00 am
enta
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Low
Report
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
2/9
07:06 pm
enta
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
2/9
04:16 pm
enta
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals: Fiscal Q1 Earnings Snapshot [Yahoo! Finance]
2/9
04:01 pm
enta
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Low
Report
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
1/9
08:02 am
enta
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Enanta Pharmaceuticals (NASDAQ:ENTA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
1/8
07:27 am
enta
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook [Yahoo! Finance]
Low
Report
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook [Yahoo! Finance]
1/8
07:00 am
enta
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
Low
Report
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook
1/5
07:13 am
enta
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/5
07:00 am
enta
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/1
08:35 am
enta
Enanta Pharmaceuticals Insider Ups Holding During Year [Yahoo! Finance]
Medium
Report
Enanta Pharmaceuticals Insider Ups Holding During Year [Yahoo! Finance]